NEWSROOM

Insights, events, and firm news for life sciences, pharmaceutical, chemical, and technology innovators.

AI-ASSISTED DRUG DISCOVERY PATENTS: FROM ALGORITHM TO ASSET

AI can accelerate discovery, but it can’t be the inventor. This guide explains how inventorship works in AI-assisted drug discovery, what can go wrong in real workflows, and how in-house teams can document human decision-making to protect patent enforceability and deal readiness.

Read More

HOW TO CONDUCT IP DUE DILIGENCE FOR LIFE SCIENCES AND ADVANCED MATERIALS COMPANIES

In life sciences and advanced materials sector, IP due diligence is more than a legal formality; it’s central to valuation, deal viability, and long-term competitiveness. This article outlines a practical roadmap for investors and growth-stage companies to assess IP assets, FTO, risk, and strategy with the rigor these transactions demand.

Read More

BIOTECH & PHARMA IP STRATEGIES: LEVERAGING LICENSING, COLLABORATION, AND PLATFORMS BEYOND THE MOLECULES

Intellectual property is the foundation of biotech success. Discover how platform-driven IP strategies, licensing frameworks, and strategic collaborations can amplify valuation, attract investors, and accelerate commercialization. Learn how Hylton Rodic Law helps biotech innovators protect the science, structure the deal, and scale the business.

Read More

AI-GENERATED PRIOR ART IN PATENT LAW: HIDDEN RISKS YOU CAN’T IGNORE

AI can accelerate innovation, but it can also introduce synthetic prior art that undermines biotech IP. Explore key risks in operability, public access, and misuse. Learn how to protect your patent filings with expert strategies.

Read More

REFLECTIONS FROM MUNICH: A SUMMIT ON LIFE SCIENCES STRATEGY ON IP & EXCLUSIVITY

We’ve just returned from the Life Sciences Strategy Summit in Munich, where Keisha Hylton-Rodic joined global experts to explore divisional patenting and the evolving IP landscape. The conversations were rich, the insights actionable, and the collaboration inspiring.

Read More

PHARMA IN A POST-PATENT CLIFF WORLD: PATENT CLIFF STRATEGIES FOR BIOTECH IP PROTECTION

As billions in drug patents expire, the pharmaceutical industry faces a looming patent cliff. Biotech innovators must rethink IP protection to safeguard revenue and innovation. This article explores trade secrets, continuous filings, data ownership, and regulatory exclusivity, strategies that help companies adapt and thrive beyond patent loss.

Read More

WHY GREAT PATENTS FAIL: HOW TO BUILD A WINNING IP STORY IN PATENT PORTFOLIO STRATEGY

Strong patents aren't always enough. In biotech and pharma, success hinges on how well your IP tells a story. Learn why great inventions fail in the market, how to craft a compelling IP narrative, and what investors and licensing partners really want to hear. Discover Hylton-Rodic Law’s approach to building winning patent strategies.

Read More

RISK MITIGATION IN VENTURE STUDIO DEALS

Intellectual property risks are rising in venture studio models, often unnoticed until it’s too late. This guide explains how to structure IP ownership, avoid earnout traps, and protect trade secrets before deals go sideways. Startups, investors, and studios: don’t skip this legal checklist.

Read More

SUNSHINE FRIDAYS, REAL IMPACT

At Hylton-Rodic Law, we believe sustainable legal excellence starts with well-being. That’s why we created Sunshine Fridays, our summer policy where the team logs off at 1:00 PM ET each Friday. It’s part of our broader micro-wellness approach: small, consistent habits that support mental health, fuel focus, and foster a healthier way to practice law.
From quarterly mental health days to birthday PTO and a firmwide holiday week off, our wellness culture isn’t just a perk; it’s our strategy for meaningful, human-centered legal work.

Read More